www fc188 ph log in NEW YORK , Dec. 9, 2024 /PRNewswire/ -- To transform the landscape of algorithmic trading, global Fintech leader Broadridge Financial Solutions, Inc. (NYSE: BR ), today announced the launch of an innovative AI-powered algorithm insights service for NYFIX. Driven by real-time liquidity mapping, the service is designed to empower asset managers, hedge funds, and other buy-side firms to achieve unprecedented accuracy, seamless workflow integration, and proven cost-efficiency. "Algo traders will now have a quantitative, data-driven service to power critical trading decisions," said George Rosenberger, Head of NYFIX, Broadridge Trading and Connectivity Solutions. "By harnessing the power of AI and historical insights, we're giving our clients the tools they need to navigate complex markets with greater precision and confidence. This innovative solution not only optimizes trading strategies, but also reduces costs, making it an invaluable asset for the buy-side." This is the first and only solution of its kind, using advanced AI to leverage public and private data to understand the liquidity landscape, particularly potential dark fill location. This approach identifies the ideal algorithmic execution for any given order, reducing outliers to improve overall trading costs. Traders benefit from real-time alerts and in-trade analysis, allowing for in-flight adjustments to stay aligned with their objectives, ensuring optimal strategy selection throughout the trading process. The NYFIX service was developed based on decades of proven research from Jeff Alexander and Linda Giordano , whose pioneering work at Babelfish Analytics established the standard for understanding routing dynamics, analyzing venue liquidity, and optimizing algorithm selection. This collaboration brings together unique and proprietary trader-focused insights with the trusted and transformational technological capabilities and extensive distribution capacity of Broadridge, creating a powerful service to enhance the trader's ability to improve performance. Available to NYFIX Order Routing customers in the U.S. equities market, the solution's framework is built to expand rapidly across other asset classes and regions, with future plans to extend access to clients on other Order Routing Networks. About Broadridge Broadridge Financial Solutions (NYSE: BR ), is a global technology leader with the trusted expertise and transformative technology to help clients and the financial services industry operate, innovate, and grow. We power investing, governance, and communications for our clients – driving operational resiliency, elevating business performance, and transforming investor experiences. Our technology and operations platforms underpin the daily trading of more than $10 trillion of equities, fixed income and other securities globally. A certified Great Place to Work®, Broadridge is part of the S&P 500® Index, employing over 14,000 associates in 21 countries. For more information about us, please visit www.broadridge.com . Broadridge Contacts: Investors: Edings Thibault Head of Investor Relations, Broadridge [email protected] Media: Gregg Rosenberg Global Head of Corporate Communications [email protected] SOURCE Broadridge Financial Solutions, Inc.

Arne Slot explains why Real Madrid were a ‘pain in the a**’ after Liverpool win

Michael Adebayo Mayowa Sonariwo, popularly known as SonariwoOnDeck SOD, has become a significant player in the Nigerian entertainment landscape, transforming the events industry over the last decade. His journey began as the president of the ACS at Hull University, where he organized numerous events and house parties that laid the foundation for his future successes. After completing his master’s degree, he founded EMG Entertainment, which successfully hosted major events in both London and Lagos until the pandemic necessitated a shift towards content creation. The COVID-19 pandemic marked a pivotal moment for Sonariwo, as he leveraged social media platforms like TikTok to embark on his content creation career. His ability to resonate with audiences resulted in his content going viral from the outset, showcasing his talent for captivating storytelling and entertainment. With over ten years of experience in event organization, he has now established himself as the mastermind behind “Sunday At Ilashe,” the largest beach event in Nigeria, which continues to attract thousands of attendees. Sonariwo’s brand extends beyond mere entertainment; it serves a larger societal purpose. His events offer a much-needed respite for young Nigerians, fostering a sense of community among individuals from various backgrounds. Additionally, as an influencer, he seeks to challenge societal norms by encouraging young Nigerian men to embrace self-expression. With plans to revitalize Sunday At Ilashe and launch other major brands like MENISMS and SonariwoOnDeck, Michael Adebayo Mayowa Sonariwo is set to continue making significant strides in the entertainment industry while uplifting the voices of his generation.LARAMIE — Two of Wyoming's leaders were named to the Mountain West volleyball All-Conference team on Tuesday. Outside-hitter Paige Lauterwasser and setter Kasia Partyka were selected to the 18-women team following their outstanding 2024 seasons. The Cowgirls ended their season on Saturday with a five-set win over Nevada to finish 15-12 overall and 7-11 in conference to place eighth in the MW standings. The honor was the first for Lauterwasser, who led the Cowgirls in kills with 371. The sophomore finished third on the team with a .217 hitting efficiency, though she earned by far the most chances with 1,040 attempts over 110 sets played. Lauterwasser finished seventh in the conference with 3.44 kills per set and eighth with 3.76 points per set. She also finished her season with six double-doubles during league play, averaging 2.07 digs per set. Partyka earned all-conference honors for the second year in a row. The senior finished fourth in the MW with an average of 9.47 assists per set. She tallied at least 30 assists in 17 of 18 MW games. Partyka continued to be a superb all-around performer for the Cowgirls in '24. In addition to her assist totals, Partyka finished with 111 kills with a .230 hitting efficiency. She added 267 digs at a rate of 2.43 per set. In addition to the honors for Partyka and Lauterwasser, middle Sarah Holcomb earned MW honorable mention honors. Holcomb, a 6-foot-2 junior, ranked second in the MW with an average of 1.41 blocks per set, just behind the 1.42 average of UNLV's Rheanna Deen-Jackson. Holcomb also averaged 2.07 kills per set and ranked fifth in the MW with a .376 hitting efficiency. She was named the league's Defensive Player of the Week in the final week of the season. Colorado State senior opposite hitter Malaya Jones was named the Player of the Year in the MW. She averaged 4.66 kills and 2.29 digs per set while leading the Rams to the regular-season title. Boise State setter Kiki Remensperger, who averaged 5.12 assists, 1.27 kills and 3.08 digs per set, took home the Freshman of the Year honors. Colorado State's Emily Kohan was named the Coach of the Year after leading the Rams to the conference title with a 14-4 league record. The rest of the MW All-Conference team included: setter Brooke Cowie (Fresno State), opposite hitter Paige Bartsch (Boise State), middle Karina Leber (Colorado State), middle Tierney Barlow (Utah State), opposite hitter Adna Mehmedovic (Utah State), opposite hitter Taylor Underwood (San Diego State), middle Kelsey Watson (Utah State), outside hitter Lauryn Payne (New Mexico), middle Shea Rubright (San Diego State), libero Dionii Fraga (Fresno State), middle Naeemah Weathers (Colorado State), opposite hitter Addison Haluska (Fresno State), outside hitter Gabby McLaughlin (Nevada), outside hitter Ella Rud (Fresno State) and setter Emery Herman (Colorado State).

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company's FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company's off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. "We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation,” said Bob Valamehr, President of Research and Development of Fate Therapeutics. "We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization.” FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company's FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study's conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled " Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ”, the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled " Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ”, the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics' iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company's proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company's platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics' iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company's pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company's iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company's progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company's clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company's product candidates, the timing and availability of data from the Company's clinical trials, the therapeutic and market potential of the Company's research and development programs and product candidates, the Company's clinical and product development strategy, and the Company's expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company's research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company's product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company's product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company's ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company's product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company's periodic filings with the Securities and Exchange Commission, including but not limited to the Company's most recently filed periodic report, and from time to time in the Company's press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 [email protected]SE Louisiana earns 76-60 win over North Dakota

Stock market today: Wall Street slips as technology stocks drag on the marketWe are well-positioned to grow via key market opportunities at the forefront of global healthcare, including the incoming U.S. administration's aim to "Make America Healthy Again" by tackling chronic disease. Commercial and Community Care-Delivery: Continued expansion with market-leading employer, provider and payvider innovation partners Growth of GLP-1s: Engagement expertise provides unique ability to facilitate sustainable health outcomes and demonstrable ROI to GLP-1 sponsors Rise of Health AI: Unique data sets and capabilities will enrich and accelerate progress of next-gen clinical discovery platforms TORONTO , Nov. 27, 2024 /PRNewswire/ - Newtopia Inc. (" Newtopia " or the " Company ") (TSXV: NEWU) (OTCQB: NEWUF ), a tech-enabled whole health platform creating sustainable habits that prevent, slow and reverse chronic disease, today announced its third quarter 2024 financial results, operational highlights and filing of its financial statements. These results pertain to the three months ended September 30, 2024 . All amounts are expressed in Canadian dollars, unless otherwise noted. Third Quarter 2024 Financial Highlights: Revenue of $1.0 million Opex reduction of 16% New partnership with US supplemental payvider positions Newtopia for profitability in 2025 "As we have for eleven years, Newtopia continues to prove our unique ability to produce industry-leading patient engagement and to cultivate healthy habits that can prevent, slow and reverse chronic metabolic disease", said Jeff Ruby , Newtopia Founder and CEO. "Most recently, we reported nine-month outcomes from our ongoing trial with Arkansas -based Heartland Whole Health Institute, in which we delivered Newtopia's best-ever engagement rates and weight loss outcomes in both provider and employer environments." "This quarter we also further strengthened our underlying operations, and evolved our offerings to respond to emerging industry opportunities and value-based needs, including the incoming US administration's desire to 'Make America Healthy Again' by tackling chronic disease – something we do better than anyone else in the market", continued Ruby. "Building on the strength of this progress we continue to pursue three significant opportunities to accelerate Newtopia growth in the final quarter of the year and into 2025: (1) expanding our key innovation partnerships with providers, employers and provincial payers, including a new relationship with a US Supplemental Payvider covering millions of employee lives; (2) combining Newtopia's proven habit change platform with GLP-1 drugs for obesity and type 2 diabetes; and (3) partnering with health AI and clinical discovery innovators to improve our collective ability to deliver best in breed outcomes that prevent, reverse and slow chronic disease", Ruby concluded. Third Quarter 2024 Financial Results Revenue for the three months ended September 30, 2024 was $1.0 million compared to $2.4 million in the prior-year period. This decrease is driven by the loss of a client effective June 2024 , in addition to a structural incentive change with an existing client which the Company is actively working to offset. Gross profit for the third quarter was $0.3 million , or 34% of revenue. Gross profit consists of revenue less direct expenses, including the cost of Welcome Kits and labor costs associated with the Company's frontline health coaching team. Adjusted operating expenses for the three months ended September 30, 2024 , totaled $1.3 million , compared to $1.6 million in the prior-year period. The Company posted an adjusted operating loss of $987 thousand , compared to a gain of $21 thousand in the prior-year period. Given the new partnership with a US payvider, Newtopia anticipates returning to profitable growth in the near future. Conference Call The Company will host a conference call November 27 at 5 p.m. eastern time to discuss the third quarter 2024 results in further detail. To access the conference call, please dial (800) 717-1738 (U.S.) or (646) 307-1865 (International) 10 minutes prior to the start time and reference Conference ID number 15026. The call will also be available via live webcast on the investor relations portion of the Company's website located at investor.newtopia.com . A replay of the conference call will be available through December 18, 2024 , which can be accessed by dialing (844) 512-2921 (U.S.) or (412) 317-6671 (International) and entering the passcode 11157569. The webcast will also be archived on the Company's website. About Newtopia Newtopia is a personalized whole health platform helping people create positive lifelong habits that prevent, slow, or reverse chronic disease while reducing healthcare costs. The platform leverages genetic, social and behavioral insights to create individualized prevention programs with a focus on metabolic disease, diabetes, mental health challenges, hypertension, weight management and musculoskeletal disorders. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. Newtopia serves some of the largest nationwide employers and health plans and is currently listed in Canada on the Toronto Stock Exchange (TSXV: NEWU) and is quoted in the US on the OTCQB ® Venture Market (OTCQB: NEWUF ). To learn more, visit newtopia.com , LinkedIn or X . Forward Looking Statements This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable United States securities legislation (collectively, "forward-looking statements"), which reflects management's expectations regarding Newtopia's future growth, results from operations (including, without limitation, future production and capital expenditures), performance (both operational and financial) and business prospects and opportunities. Wherever possible, words such as "predicts", "projects", "targets", "plans", "expects", "does not expect", "budget", "scheduled", "estimates", "forecasts", "anticipate" or "does not anticipate", "believe", "intend" and similar expressions or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. All statements other than statements of historical fact may be forward- looking information. Such statements reflect Newtopia's current views and intentions with respect to future events, based on information available to Newtopia, and are subject to certain risks, uncertainties, and assumptions. Material factors or assumptions were applied in providing forward-looking information. While forward-looking statements are based on data, assumptions and analyses that Newtopia believes are reasonable under the circumstances, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Forward-looking statements are not a guarantee and are based on a number of estimates and assumptions management believes to be relevant and reasonable, whether actual results, performance or developments will meet Newtopia's expectations and predictions depends on a number of risks and uncertainties that could cause the actual results, performance and financial condition of Newtopia to differ materially from its expectations. Certain of the "risk factors" that could cause actual results to differ materially from Newtopia's forward-looking statements in this press release include, without limitation: the termination of contracts by clients, risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters- in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; and other general economic, market and business conditions and factors, including the risk factors discussed or referred to in Newtopia's disclosure documents, filed with the securities regulatory authorities in certain provinces of Canada and available at www.sedarplus.ca including Newtopia's final long form prospectus dated March 30, 2020 . For more information on these risks please see the "Risk Factors" in Newtopia's final long-form prospectus dated March 30, 2020 . Should any factor affect Newtopia in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this news release is made as of the date of this news release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Key Financial Measures and Schedule of Non-GAAP Reconciliations Unaudited Gross Profit Information- including amortization Reconciliation of Total Operating Expenses to Adjusted Operating Expenses Unaudited Adjusted Operating Loss Newtopia Inc. Condensed Interim Consolidated Statements of Financial Position (Unaudited) As at September 30, 2024 and December 31, 2023 (Expressed in Canadian Dollars) Newtopia Inc. Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Unaudited) Three Months Ended September 30, 2024 (Expressed in Canadian Dollars) Newtopia Inc. Condensed Interim Statements of Cash Flows (Unaudited) Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) SOURCE Newtopia Inc.